ExcelMale
Menu
Home
What's new
Latest activity
Forums
New posts
Search forums
What's new
New posts
Latest activity
Videos
Lab Tests
Doctor Finder
Buy Books
About Us
Men’s Health Coaching
Log in
Register
What's new
Search
Search
Search titles only
By:
New posts
Search forums
Menu
Log in
Register
Navigation
Install the app
Install
More options
Contact us
Close Menu
Forums
Peptide Forums (GHRH, Sermorelin, etc)
General Peptide Use & Information
Revolutionizing Growth Hormone Deficiency Treatment
JavaScript is disabled. For a better experience, please enable JavaScript in your browser before proceeding.
You are using an out of date browser. It may not display this or other websites correctly.
You should upgrade or use an
alternative browser
.
Reply to thread
Message
<blockquote data-quote="madman" data-source="post: 259153" data-attributes="member: 13851"><p>[MEDIA=youtube]kt_OQBBj7rg[/MEDIA]</p><p></p><p><em>LUM 201 (ibutamoren) is a focus of recent research for treating idiopathic pediatric growth hormone deficiency. This rare endocrine disorder, characterized by insufficient growth hormone secretion from the anterior pituitary gland, can manifest at birth, as a result of a medical condition or brain injury, or be idiopathic. It leads to growth retardation, short stature, and various associated health issues such as metabolic abnormalities, impaired cardiovascular function, fatigue, delayed puberty, osteoporosis, and reduced muscle strength. The research aims to explore the efficacy of LUM 201 in addressing these challenges.</em></p><p></p><p></p><p></p><p></p><p><strong>Key points:</strong></p><ul> <li data-xf-list-type="ul"><em><em>LUM-201 (ibutamoren) is an investigational small molecule that stimulates Growth Hormone (GH) secretion.</em></em></li> <li data-xf-list-type="ul"><em><em>Studies presented at ENDO 2023 demonstrated the effectiveness of LUM-201 in treating idiopathic pediatric growth hormone deficiency.</em></em></li> <li data-xf-list-type="ul"><em><em>Two Phase 2 trials analyzed the annualized height velocity (AHV) for two different doses (1.6 mg/kg/day and 3.2 mg/kg/day).</em></em></li> <li data-xf-list-type="ul"><em><em>AHV results showed 8.1±1.9 cm/year for the lower dose and 8.0±1.5 cm/year for the higher dose initially, and 7.8±1.7 cm/year and 7.4±1.2 cm/year after 12 months of treatment.</em></em></li> <li data-xf-list-type="ul"><em><em>LUM-201 was well tolerated with no safety concerns.</em></em></li> <li data-xf-list-type="ul"><em><em>A predictive enrichment marker (PEM) identified 1.6 mg/kg/day as the optimal dose for efficacy and durability.</em></em></li> </ul></blockquote><p></p>
[QUOTE="madman, post: 259153, member: 13851"] [MEDIA=youtube]kt_OQBBj7rg[/MEDIA] [I]LUM 201 (ibutamoren) is a focus of recent research for treating idiopathic pediatric growth hormone deficiency. This rare endocrine disorder, characterized by insufficient growth hormone secretion from the anterior pituitary gland, can manifest at birth, as a result of a medical condition or brain injury, or be idiopathic. It leads to growth retardation, short stature, and various associated health issues such as metabolic abnormalities, impaired cardiovascular function, fatigue, delayed puberty, osteoporosis, and reduced muscle strength. The research aims to explore the efficacy of LUM 201 in addressing these challenges.[/I] [B]Key points:[/B] [LIST] [*][I][I]LUM-201 (ibutamoren) is an investigational small molecule that stimulates Growth Hormone (GH) secretion.[/I][/I] [*][I][I]Studies presented at ENDO 2023 demonstrated the effectiveness of LUM-201 in treating idiopathic pediatric growth hormone deficiency.[/I][/I] [*][I][I]Two Phase 2 trials analyzed the annualized height velocity (AHV) for two different doses (1.6 mg/kg/day and 3.2 mg/kg/day).[/I][/I] [*][I][I]AHV results showed 8.1±1.9 cm/year for the lower dose and 8.0±1.5 cm/year for the higher dose initially, and 7.8±1.7 cm/year and 7.4±1.2 cm/year after 12 months of treatment.[/I][/I] [*][I][I]LUM-201 was well tolerated with no safety concerns.[/I][/I] [*][I][I]A predictive enrichment marker (PEM) identified 1.6 mg/kg/day as the optimal dose for efficacy and durability.[/I][/I] [/LIST] [I][/I] [/QUOTE]
Insert quotes…
Verification
Post reply
Share this page
Facebook
Twitter
Reddit
Pinterest
Tumblr
WhatsApp
Email
Share
Link
Sponsors
Forums
Peptide Forums (GHRH, Sermorelin, etc)
General Peptide Use & Information
Revolutionizing Growth Hormone Deficiency Treatment
This site uses cookies to help personalise content, tailor your experience and to keep you logged in if you register.
By continuing to use this site, you are consenting to our use of cookies.
Accept
Learn more…
Top